Newsletter Subject

Huge News Solving A Major National Crisis Leads Ensysce Biosciences Inc. (NASDAQ: ENSC) To A Massive Day!

From

financialdrivenresearch.com

Email Address

newsletter@financialdrivenresearch.com

Sent On

Mon, May 20, 2024 08:07 PM

Email Preheader Text

This Sub-dollar Stock Is Making A Huge Impact To Cure The Opioid Crisis Huge News Solving A Major Na

This Sub-dollar Stock Is Making A Huge Impact To Cure The Opioid Crisis Huge News Solving A Major National Crisis Leads Ensysce Biosciences Inc. (NASDAQ: ENSC) To A Massive Day! Hi “FDR” Member, Ensysce Biosciences Inc. (NASDAQ: ENSC) had a solid day today off of great news regarding their solution to the opioid crisis, which is a national issue all in itself. From the $0.624 close on Friday, $ENSC hit highs of $0.75 today, yielding potential gains of over +20%. Keep an eye out for our next big winner!!! [New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR]( Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product. PF614-MPAR is the Company's Multi-Pill Abuse Protection (MPAR) unique combination opioid product which shuts off opioid release when too many pills are ingested, thereby stopping deliberate or accidental overdose. This ground-breaking technology has the potential to save many lives and was recently granted Breakthrough Therapy designation by the U.S. Food & Drug Administration (FDA). The Phase 1b study, PF614-MPAR-102, will evaluate opioid release following administration of PF614-MPAR at doses of 25 mg, 50 mg and 100 mg delivered twice daily for 5 days to verify both overdose protection and effective delivery of oxycodone. The study will apply the Quotient Sciences Translational Pharmaceutics® platform to manufacture and test the PF614-MPAR drug product to expedite the clinical study process. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, remarked, "My team is delighted to continue our partnership with Quotient Sciences and the use of their unique approach to drug product optimization. Our aim is to provide prescribers and patients with an innovative, safer choice to treat severe pain and reduce substantial concern of overdose. As prescription opioid overdoses remain a critical issue in America, the resultant regulatory restrictions are now causing supply issues for patients in severe pain. The potential benefits of our MPAR platform were highlighted by Dr. Rick Dart at the PAINWeek conference in 2023." About Breakthrough Therapy Breakthrough Therapy is a rarely used designation, having been granted to fewer than 300 drugs since the category was established in 2012. It is designed to expedite the development and review of drugs that are intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. About Quotient Sciences Quotient Sciences is a global drug development and manufacturing accelerator that supports companies across the drug development pathway. They provide integrated contract research, development, and manufacturing services for many of the leading global pharma and biotech companies, bringing deep expertise and insight to the development process. The Quotient partnership was instrumental in aiding the development of the first PF614-MPAR 25 mg dosage form using their unique "Translation Pharmaceutics®" process. About Ensysce Biosciences Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit [www.ensysce.com](. A Lethal Weapon In The Battle Against Opioid Abuse And Overdose  Why? Because companies, like Ensysce Biosciences, that can help to effectively mitigate the devastating consequences of opioid abuse stand to earn billions. That's not an exaggeration, either. Not only is the U.S. starved for answers on how to curb the abuse, but many other countries are as well. And the amount of money they are willing to pay to eradicate opioid abuse can be nearly limitless into the end of this decade. Call it a full-court pressure, with funds front-loaded, to end this crisis sooner rather than later. That can play directly into Ensysce Biosciences' waiting marketing hands and bank accounts. Look, at $0.62 a share at Friday's close, an investor might think this company is too small to have an impact. I get it, some think small can't compete. However, in the biotech world, small companies can become large on a single headline. Fortunes are literally made overnight by investors being rewarded for investing foresight ahead of a new drug or treatment approval. So, no—Ensynsce Biosciences isn't too small for anything. In fact, it is priced and positioned to yield potentially exponential increases in company size and share value. That trend is underway. The company's stock surged over 21% since May 10th as more investors realize that it is on the path to offering some of the most innovative, abuse-resistant opioid solutions that promise to revolutionize pain management. FDA Grants Breakthrough Therapy Designation The company's Breakthrough Technologies, its flagship PF614, and PF614-MPAR, are expected to be absolute game-changers in the pain relief market. They are so potentially potent that the FDA granted PF614-MPAR Breakthrough Therapy designation, recognizing its potential to significantly improve severe pain management with built-in overdose protection. If you don't think that's a big deal, consider this: Since its inception, the Breakthrough Therapy designation has been awarded to fewer than 300 drugs. So, earning its way on that list is more than impressive; it's valuable from an investor's perspective because it accelerates the development and review process and, perhaps more importantly, can attract deep-pocketed Big Pharma interest. Remember, despite Big Pharma having ushered in the crisis, many now see their path to redemption is to help cure it. As contradictory as it may sound to their own profit motives, it's not. If Big Pharma can provide or partner with a company delivering to the market an abuse-deterrent drug with the same sales potential, that can be the most profitable win-win proposition ever created. Of course, the alternative must be effective. Ensynsce Biosciences' checks that box. Its PF614 is developed using the Trypsin-Activated Abuse Protection (TAAP™) technology to provide the same pain relief as traditional opioids like oxycodone but with extended-release and abuse-resistant properties. Phase 3 clinical trials for PF614 are planned to start in the back half of this year. Here's even better news: The FDA's constructive feedback and guidelines for these trials have provided a clear roadmap toward earning approval, significantly reduced regulatory risks, and have helped pave a clear pathway toward commercialization. Ensynsce Biosciences Has Stacked The Deck Those are value cards that few, if any, Ensynsce Biosciences competitors can play. Frankly, most still need a comparable technology deck to even play from. Remember, that's what makes the Ensynsce Biosciences candidate different. Its innovative combination of PF614 with the Multi-Pill Abuse Resistance (MPAR®) technology actually prevents overdose through a mechanism that "turns off" the release of oxycodone if more than the prescribed dose is consumed. That could save many of the over 107,000 lives lost in 2023. More than saving a human toll, it could help rehabilitate countless individuals, affected families, and communities. Thus, Ensysce Biosciences' isn't only a safer opioid alternative from a scientific perspective, it can be a crucial contributor to the humanitarian effort that can provide hope to millions, save billions of dollars that go toward rehab and incarcerations, and, most importantly, provide essential pain relief to those that need it without the fear of government intrusion that tells doctors what and how much medicine to prescribe. Ironically, microcap company Ensysce Biosciences is leading the charge in helping win this critical battle against the opioid crisis. And after a successful capital raise and strategic financial management, they appear to have one of the clearest paths toward regulatory approval for a drug that could eclipse blockbuster-level sales (a billion or more) within weeks of commercialization. Phase 3 Valuation Could Send The ENSC Stock Price Soaring Remember, fellow investors, Ensysce Biosciences isn't starting its clinical trial ambitions; it's about to enter Phase 3. It's no secret that the difference in valuations of a Phase 3 company compared to a Phase 2 one can be tens or even hundreds of millions. In other words, don't be surprised to wake up to an ENSC share price of 2X, 3X, or even 10X higher. That potential is indeed in play based on what is likely to be massive interest in this company's late-stage drug pipeline. Don't forget- Ensysce Biosciences is guided to start Phase 3 by mid-year, just weeks away. Still, investing in partnership or buyout speculation is the smallest part of the value proposition exposed. Investors should also be focused on the vast revenue-generating potential in this company's crosshairs. Know this: Going on this project alone certainly wouldn't be the worst option. While it may trigger some dilution, the windfall upon commercialization would most likely dwarf that cost. Thus, with Ensysce Biosciences charging toward a Phase 3 trial with proprietary next-gen drug development platforms, its stock at current prices may present more than a bargain; it may be as ground floor as it gets. And with expected milestones in the queue that could immediately steepen the share price curve, re-claiming its 52-week high of $2.84, 350% higher than its current price, could be a near-term target already in the crosshairs. To Your Trading Success, Michael Reece Editor, Financial Driven Research © 2024 Financial Driven Research, All Rights Reserved. Financial Driven Research (“FDR” or “Company”) is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inves∙tment for any specific individual. FDR full disclosure is to be read and fully understood before using FDR website or joining FDR email or sms list. By viewing FDR website and/or reading FDR email or sms list you are agreeing to FDR full disclosure This publication may contain information regarding inves∙tment ideas and third-party ratings regarding specific securities. We hold n∙o inves∙tment licenses and are thus neither licensed nor qualified to provide inves∙tment adv∙ice. FDR nor its principals are not FINRA-registered broker-dealers or inves∙tment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from FDR to buy or sell any security. Always be extremely careful and consult a licensed inves∙tment professional before making any inves∙tment decision as inves∙ting in securities carries a high degree of risk; you may likely lose some or all of the inves∙tment. This communication is a sponsored advertisement. FDR and/or its subsidiaries and/or affiliates have been compensated $20,000 USD to disseminate this communication. Please note we do not hold positions in stocks we profile. We do not trade in any of our sponsored advertisements, or non-sponsored profiles. We do not accept stock as a form of payment for our sponsored advertisements. Please review the full disc∙laimer at [Disc]( and Disclosure Policy]( for important information regarding this sponsored advertisement. © 2023 FDR. All rights reserved., 1014 W 36th St, Baltimore, MD 21211, United States You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](

EDM Keywords (192)

Marketing emails from financialdrivenresearch.com

View More
Sent On

13/06/2024

Sent On

13/06/2024

Sent On

13/06/2024

Sent On

13/06/2024

Sent On

06/06/2024

Sent On

06/06/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.